Academic Journal
Q1Cancer Research
About Cancer Research
Cancer Research is a scholarly journal published by American Association for Cancer Research Inc.. SCImago 2025 places it in Q1 with an SJR of 4.347 and an H-index of 522.
Its listed coverage is 1941-2026 and its research categories include Cancer Research (Q1); Oncology (Q1). The 2025 dataset reports 364 documents and 11313 citations across the latest three-year reporting window.
Cancer remains one of the most challenging health issues worldwide, affecting millions of lives every year. However, cancer research has made tremendous progress in recent decades, offering new hope for prevention, early detection, and treatment. With the rise of cutting-edge technologies and global collaboration, the field of cancer research continues to evolve, bringing us closer to a future without cancer.
What is Cancer Research?
Cancer research is a branch of medical science that focuses on understanding the causes of cancer, how it develops, and how it can be treated or prevented. Researchers study the behavior of cancer cells, their genetic makeup, and how they interact with the body. This knowledge helps in developing targeted therapies, innovative treatments, and personalized medicine for cancer patients.
Key Areas of Cancer Research
-
Basic Research: This involves studying the biology of cancer cells to understand what makes them grow and spread. Discoveries in this area often lead to breakthroughs in diagnosis and treatment.
-
Clinical Research: Clinical trials are conducted to test new drugs, treatment methods, or medical devices. Patients participating in trials help researchers determine the effectiveness and safety of these treatments.
-
Translational Research: This bridges the gap between lab discoveries and clinical application. It ensures that scientific findings are turned into real-world solutions quickly and efficiently.
-
Prevention and Early Detection: Research in this area aims to identify risk factors and develop screening tools. Early detection significantly improves the chances of successful treatment.
-
Immunotherapy and Targeted Therapy: These are revolutionary approaches where the body’s immune system is used to fight cancer or where treatments target specific cancer cell markers, reducing side effects.
Recent Breakthroughs in Cancer Research
In recent years, cancer research has achieved some remarkable milestones:
-
CAR-T Cell Therapy: A form of immunotherapy that uses the patient’s own immune cells to target and destroy cancer cells.
-
Liquid Biopsies: A non-invasive method to detect cancer through a blood test, improving early diagnosis.
-
AI in Cancer Research: Artificial intelligence is being used to analyze large datasets and predict the best treatment options for patients.
Importance of Cancer Research
Cancer research not only helps in saving lives but also improves the quality of life for patients. It reduces the financial and emotional burden on families and healthcare systems. Furthermore, cancer research promotes public awareness, helping people adopt healthier lifestyles and take preventive measures.
How You Can Support Cancer Research
There are several ways to support the fight against cancer:
-
Donate to reputable cancer research foundations.
-
Participate in awareness campaigns.
-
Join clinical trials if eligible.
-
Advocate for more research funding and policies supporting cancer care.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Cancer remains one of the most challenging health conditions in the world today. With millions diagnosed each year, the need for advanced research and innovative treatments is more critical than ever. Scope Cancer Research is at the forefront of this global battle, striving to transform the future of cancer care through cutting-edge research, groundbreaking clinical trials, and a commitment to saving lives.
What is Scope Cancer Research?
Scope Cancer Research is a leading organization dedicated to understanding cancer at its core. It focuses on multiple dimensions of oncology—from early detection and diagnosis to targeted therapies and precision medicine. With a team of world-renowned scientists, doctors, and researchers, Scope is redefining how cancer is studied and treated.
Mission and Vision
The mission of Scope Cancer Research is to eliminate cancer through comprehensive research and innovative treatment strategies. The organization envisions a world where cancer is no longer a death sentence, but a treatable and even preventable disease. Their vision is supported by strategic partnerships with hospitals, universities, and pharmaceutical companies worldwide.
Breakthroughs in Cancer Treatment
Scope Cancer Research has contributed significantly to several advancements in oncology. Through in-depth molecular studies and genetic profiling, Scope’s researchers are identifying how cancers grow and mutate. This allows them to develop targeted therapies that are more effective and cause fewer side effects than traditional chemotherapy.
One of their most notable contributions is in immunotherapy, a revolutionary treatment that empowers the body’s immune system to fight cancer cells. Additionally, Scope is involved in AI-powered diagnostics, which help doctors detect cancer earlier and with greater accuracy.
Clinical Trials and Patient Impact
Scope Cancer Research actively conducts clinical trials to bring new treatments to market faster. These trials are crucial for patients who have not responded to conventional treatments. By participating in clinical trials, patients gain access to experimental therapies that could improve survival and quality of life.
Patient-centered care is at the heart of Scope’s philosophy. From counseling and support to personalized treatment plans, Scope Cancer Research ensures that every patient receives the best care possible.
Collaboration and Global Impact
Cancer is a global issue, and Scope Cancer Research understands the importance of international collaboration. The organization works with global research institutions to share data, resources, and knowledge. This collaborative approach accelerates discovery and brings hope to patients worldwide.
The Future of Scope Cancer Research
Looking ahead, Scope Cancer Research is investing in next-generation technologies like genome editing (CRISPR) and liquid biopsy to catch cancer earlier and treat it more effectively. Their ongoing research promises to reshape the landscape of cancer treatment in the coming decades.
Recent Research Articles
Latest publications matched automatically by ISSN.
Targeting Both Oncogenic Signaling and Dependence Receptor Function is Required to Fully Suppress MET Exon 14 Skipping-Driven tumorigenesis
Rémi Tellier, Marie Fernandes, Audrey Vinchent, Sonia Paget et al.
2026-09-08 · DOI: 10.1158/0008-5472.can-26-0195Extracellular Matrix Remodeling in Tumors: Forces Beyond Fibroblasts
Sonal Srivastava, Alyaa Dawoud, Andrew C. Dudley, Mitsuo Yamauchi et al.
2026-09-08 · DOI: 10.1158/0008-5472.can-26-1532Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
Jenna M. Whalen, Tokio Sano, Nathan MacGilvary, Christi A. Silva et al.
2026-09-08 · DOI: 10.1158/0008-5472.can-26-0585Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Valerio Sabatino, Cong Tang, Rita C. Acúrcio, Ana R. Coelho et al.
2026-09-04 · DOI: 10.1158/0008-5472.can-25-5578Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps
Shangheng Shi, Jingrui Yan, Yu Zhang, Yaqi Zhang et al.
2026-09-04 · DOI: 10.1158/0008-5472.can-26-0151RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Noncanonical Hedgehog Signaling
Taochen He, Qiangda Chen, Yanfei An, Zhihang Xu et al.
2026-09-03 · DOI: 10.1158/0008-5472.can-26-0333Histone Lactylation in Cancer-Associated Fibroblasts Induces Extracellular Matrix Remodeling and Immunosuppression to Promote Colorectal Cancer Progression
Chaofan Peng, Tuo Wang, Zhihao Chen, Sheng Yang et al.
2026-09-03 · DOI: 10.1158/0008-5472.can-25-5248Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Shawna K. Brookens, David A. DeGaramo, Kiesha Wilson, Austin L. Good et al.
2026-09-03 · DOI: 10.1158/0008-5472.can-25-4782Transcriptomic Profiling of Mouse Mammary Tumors Enables Prognostic and Predictive Biomarker Discovery for Human Breast Cancer
Matthew D. Sutcliffe, Kevin R. Mott, Tulay Yilmaz-Swenson, Brooke M. Felsheim et al.
2026-09-03 · DOI: 10.1158/0008-5472.can-26-0855CDState Resolves Malignant Cell Heterogeneity from Bulk Tumor RNA Sequencing Data
Agnieszka Kraft, Josephine Yates, Florian Barkmann, Valentina Boeva et al.
2026-09-03 · DOI: 10.1158/0008-5472.can-25-4102Single-Cell Analysis Guides Organoid CRISPR Screening to Reveal NF1 as a Gatekeeper of Cervical Squamous Malignant Transformation
Bai Hu, Liang Chen, Renjie Wang, Zhijun Zhou et al.
2026-09-03 · DOI: 10.1158/0008-5472.can-25-5315Editor’s Note: miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells
Amriti R. Lulla, Michael J. Slifker, Yan Zhou, Avital Lev et al.
2026-09-02 · DOI: 10.1158/0008-5472.can-26-2728Varying Cancer Drug Doses to Balance Tumor Control and Resistance Evolution
Amy E. Pomeroy, Adam C. Palmer
2026-09-02 · DOI: 10.1158/0008-5472.can-26-2187Editor’s Note: Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2 -Amplified Breast Cancers
Meghan Morrison Joly, Donna J. Hicks, Bayley Jones, Violeta Sanchez et al.
2026-09-02 · DOI: 10.1158/0008-5472.can-26-2785Histone Lactylation Mediated by circRNA-Facilitated FXR1 Phase Separation Promotes Colorectal Cancer Progression
Tao Jiang, Jianquan Liu, Qihang Hu, Junwen Qi et al.
2026-09-01 · DOI: 10.1158/0008-5472.can-25-3151Epigenetic Repression of Type I Interferon Signaling by RUNX2 Drives Immune Checkpoint Blockade Resistance in Osteosarcoma
Shasha Wang, Hualong Yan, Payel Mondal, Gamze Ayaz et al.
2026-09-01 · DOI: 10.1158/0008-5472.can-25-3970Targeting GEM Reprograms Macrophages and Overcomes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma
Linfeng Wu, Changhao Ren, Yifei Zhang, Gaojia Wang et al.
2026-09-01 · DOI: 10.1158/0008-5472.can-25-5396Fasting-Mimicking Diets Reprogram Cancer-Associated Fibroblasts to Reverse the Immunosuppressive Tumor Microenvironment in Breast Cancer
Junsheng Zhang, Ning Li, Rongrong Li, Yitian Chen et al.
2026-09-01 · DOI: 10.1158/0008-5472.can-25-5945The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity
Jia Liu, Jingbo Ma, Shuming Lin, Wei Dai et al.
2026-09-01 · DOI: 10.1158/0008-5472.can-25-5580Microenvironmental Prostaglandin F2α Antagonizes FSP1 in Cancer Cells to Sensitize Tumors to Ferroptosis and Immunotherapy
Yu Meng, Qian Zhou, Deze Zhao, Hui Su et al.
2026-08-31 · DOI: 10.1158/0008-5472.can-25-5697Reviews
Community Reviews
Version History
April 22, 2025 at 10:05 am
April 22, 2025